Pharmaceutical capsule compositions containing loratadine and psuedoephedrine
US6251427A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2000 |
| Grant date | Jun 26, 2001 |
| Priority date | — |
| Expiry date | Feb 22, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5078
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical capsule composition for oral administration exhibiting controllable, satisfactory release profiles of both loratadine and pseudoephedrine or its salts, which comprises: (a) a plurality of rapid-release pellets (pellets A), each pellet containing (i) a therapeutically effective amount of loratadine, (ii) pseudoephedrine or a pharmaceutically acceptable salt thereof, and (iii) one or more pharmaceutically acceptable excipients; and (b) a plurality of extended-release pellets (pellets B), each pellet containing (i) pseudoephedrine or a pharmaceutically acceptable salt thereof and (ii) one or more pharmaceutically acceptable excipients, which are coated with a water-insoluble polymer in an amount ranging from 2 to 30 wt % and a wet-blocking agent selected from the group consisting of magnesium stearate, talc, fatty acid ester and a mixture thereof in an amount ranging from 2 to 30 wt %, based on the total weight of pellets B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.